# A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

> **NCT06950034** · PHASE1 · RECRUITING · sponsor: **Solu Therapeutics, Inc** · enrollment: 105 (estimated)

## Conditions studied

- Chronic Myelomonocytic Leukemia
- Chronic Myelomonocytic Leukemia (CMML)
- Chronic Myelomonocytic Leukemia-1
- Chronic Myelomonocytic Leukemia-2
- Refractory Chronic Myelomonocytic Leukemia
- CMML
- Acute Myeloid Leukemia
- Acute Myeloid Leukemia (AML)
- Acute Myeloid Leukemia Post Cytotoxic Therapy
- Acute Myeloid Leukemias
- Refractory Acute Myeloid Leukemia (AML)
- Acute Monocytic Leukemia

## Interventions

- **BIOLOGICAL:** STX-0712

## Key facts

- **NCT ID:** NCT06950034
- **Lead sponsor:** Solu Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-13
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-06-30
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06950034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06950034, "A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06950034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*